Data presented from two different studies performed by IBD Cooperative Study Group suggest that 23.5% of patients receiving a dose of 5 μg/kg of IL-10 had improvement compared with placebo [118, 119]. This evidence concerns the gene IL10 and irritable bowel syndrome.